Antti Sakari Rannikko

21PUBLICATIONS
82CO-AUTHORS
Predictive and prognostic markersPacific Peoples sport and physical activityEnvironmental epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Dec 15, 2025
Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.

Abderrahim-Oussama Batouche, Eugen Czeizler, Timo-Pekka Lehto

|Dec 10, 2025
Erectile and urinary function in patients on active surveillance for prostate cancer: results from the Finnish arm of the PRIAS trial.

Oleg Kerro, Inari Kalalahti, Utku Lokman

|Apr 14, 2025
Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.

Ivo I de Vos, Cristina Marenghi, Fabio Badenchini

|Mar 27, 2025
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK.

Ugo De Giorgi, Stephen J Freedland, Antti Rannikko

|Jan 22, 2025
Association of prostate-specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result.

Juho Pylväläinen, Kirsi Talala, Jani Raitanen

|Mar 12, 2024
Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).

Sven Löffeler, Helena Bertilsson, Christoph Müller

Pageof 4

Frequent Collaborators

11 joint publications

Tuomas Mirtti

4 joint publications

Anu Kenttämies

4 joint publications

Andrew M Erickson

4 joint publications

Timo-Pekka Lehto